Compare VRA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | BMEA |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.4M | 138.1M |
| IPO Year | 2010 | 2021 |
| Metric | VRA | BMEA |
|---|---|---|
| Price | $3.10 | $1.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | N/A | ★ $9.83 |
| AVG Volume (30 Days) | 119.2K | ★ 1.1M |
| Earning Date | 06-10-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.47 | ★ 69.19 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $416,097,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $0.87 |
| 52 Week High | $4.39 | $3.07 |
| Indicator | VRA | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 38.33 | 40.54 |
| Support Level | $3.03 | $1.23 |
| Resistance Level | $3.39 | $1.47 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 21.57 | 27.78 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.